Brickell Enters Into a License Agreement with the University Of Manchester, Inc. for Exclusive Rights to BBI-2111 (Now BBI-2000), a Novel Compound with Anti-Inflammatory Properties, for the Treatment of Dermatological Indications

By April 1, 2011 No Comments
UMIP Announces Licensing Deal with Brickell Biotech, Inc.

*note: BBI-2111 is now BBI-2000 as of July 14, 2015

Following negotiations, The University of Manchester’s intellectual property agent (UMIP) has secured a licensing deal to allow US company Brickell Biotech, Inc. (Brickell) to develop BBI-2111, a novel compound with anti- inflammatory properties derived from the human protein thioredoxin.

As a result of the deal Brickell will conduct pre-clinical testing of the compound. Dependent upon the outcome of these critical studies, Brickell, in collaboration with the University of Manchester, will define a formal clinical development plan, with the ultimate objective of bringing a novel, safe and effective topical therapy for the treatment of inflammatory skin conditions to the market place.

The compound was developed at Syngenta by scientists Ian Kimber and Rebecca Dearman, who joined the University of Manchester in 2007.

In a complementary agreement, Syngenta has assigned the intellectual property and other rights to UMIP.

On the deal, Ian Kimber commented: “We are very pleased to have entered into partnership with Brickell Biotech, Inc. The deal reflects the outstanding science projects being undertaken at the University of Manchester and the opportunities for translation research that are available. This is an exciting project and we believe that this compound has the potential to provide a novel treatment for inflammatory skin diseases such as psoriasis.”

Andrew Sklawer, Vice President, Operations at Brickell Biotech, Inc. also commented: “We are very excited about this deal and are looking forward to progressing the development of BBI-2111 as a novel therapy for inflammatory skin conditions with high unmet clinical needs. We were keen to work with the University as we recognised the specific scientific expertise and exceptional laboratory facilities that it could offer.”

– ends–

Press contact: Victoria Moffatt, Roland Dransfield PR, 0161 236 1122 or victoria.moffatt@rdpr.co.uk


The University of Manchester Intellectual Property is The University of Manchester’s agent for intellectual property commercialisation and is a division of The University of Manchester I3 Ltd (www.umi3.co.uk) – The University’s Innovation Group.

UMIP is wholly owned by The University of Manchester which has over a 20 year history of IP commercialisation.

UMIP’s role is to bring as much of the University’s ground-breaking inventions and software, as is relevant, into the commercial world. This we do principally by attracting entrepreneurs, investors and corporate venture partners to our campus and Innovation Centre (www.umic.co.uk) and then, through engagement with our academic colleagues, licensing or spinning out companies.

Since UMIP’s inception in October 2004:

Over 1,900 invention disclosures have been received (314 during 2010/2011.) UMIP has set up 27 spin-out companies and brokered 263 licences and assignments and £189M has been invested by venture funders in University of Manchester spin-outs, a number of which have received national and regional enterprise awards. It currently has over 100 projects in its portfolio at various stages of development.

The University’s IP enterprises have generated approximately £45M to the University through the sale of shares in spin-outs, licensing income and through IP grants and contracts activity.

For more information, please visit www.umip.com

Brickell Biotech, Inc.

Brickell Biotech, Inc. is a development-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative, first-in-class drug therapies for the treatment of inflammatory skin and ocular diseases with high-unmet medical utility.

For more information visit www.brickellbio.com

Download PDF (170 KB)